1-Methylpiperazine → 1-(3-bromo-1-methyl-1H-1,2,4-triazol-5-yl)-4-methylpiperazine
反応式
CN1CCNCC1.Cn1nc(Br)nc1Br>CC(C)(C)[O-].Cc1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>CN1CCN(c2nc(Br)nn2C)CC1参加物
7
反応条件
- 温度
- 100 °C
実験手順
A mixture of 3,5-dibromo-1-methyl-1H-1,2,4-triazole (142 mg, 0.59 mmol), 1-methylpiperazine (62.0 mg, 0.62 mmol), tris(dibenzylideneacetone)dipalladium(0) (81 mg, 0.09 mmol), BINAP (110 mg, 0.18 mmol) and sodium tert-butoxide (113 mg, 1.18 mmol) in toluene (8 ml) was stirred at 100 °C for 1.5hrs. LCMS indicated no desired product formation. Discarded.
出典と根拠
- ORDレコード
- ord-775ba0e2a4c14f008f392711cc2a587a
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
反応ノート
読み込み中…
